Prevalence of dry eye disease in Ontario, Canada: A population-based survey

Caffery, Barbara; Srinivasan, Sruthi; Reaume, Christopher J.; Fischer, Aren; Cappadocia, David C.; Siffel, Csaba; Chan, Clara C.

doi:10.1016/j.jtos.2019.02.011

Cited by 49 publications

(44 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…DED is a common clinical disease with a prevalence of 15% to 35%, which seriously affects the quality of life. [ 17 , 18 ] Age is known to be an important factor, but the incidence of DED is still around 15% in people under 50 years of age. [ 19 ] Therefore, the research of related risk factors is an important method, which helps us to explore the pathological mechanism and preventive treatment of DED.…”

Section: Discussionmentioning

confidence: 99%

Association between asthma with dry eye disease

Huang¹,

Yang²,

Liao

et al. 2020

Medicine

View full text Add to dashboard Cite

Backgoun: Asthma and dry eye disease are common clinical diseases. Studies have shown that asthma is related to dry eye, but there is no high-quality evidence-based medical evidence. Method: This protocol and final study will be conducted in accordance with the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols 2015 statement. We will search PubMed, EMBASE, ISI Web of Science, China National Knowledge Infrastructure for all relevant literature published from their inception up to August 1, 2020. Literature search, data extraction, and quality assessment will be carried out independently by two researchers, and a third researcher will resolve differences when necessary. The association between dry eye disease and asthma will indicate as odds ratio with 95% confidence interval and statistically analyzed using RevMan 5.3 software. If the studies included have high heterogeneity, we will conduct sensitivity analysis and subgroup analysis. Results: The protocol is intended to guide a meta-analysis aimed at identifying and quantifying the association between asthma and dry eye disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between asthma with dry eye disease

Huang¹,

Yang²,

Liao

et al. 2020

Medicine

View full text Add to dashboard Cite

show abstract

“…3 In the United States (US), approximately 16 million adults have been diagnosed with DED, with an estimated prevalence of 6.8%, while in Canada, approximately 6 million adults are affected by DED, with an estimated prevalence of 21.3%. 4,5 These estimates may underrepresent the true burden of DED as diagnosis of DED is challenging due to its multifactorial etiology and given that DED-related signs manifest in only 57% of symptomatic patients. 6 DED symptoms can be particularly heterogeneous in patients with immune-mediated diseases, such as inflammatory bowel disease or Sjogren's syndrome, and the correlation between subjective and objective parameters for DED is not always clear.…”

Section: Introductionmentioning

confidence: 99%

Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra®) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease

Hovanesian¹,

Nichols²,

Jackson³

et al. 2021

OPTH

View full text Add to dashboard Cite

Purpose This study evaluated real-world treatment of dry eye disease (DED) with lifitegrast. Patients and Methods Ophthalmologists and optometrists treating patients with DED were invited to participate through a healthcare provider (HCP)-based panel. HCPs completed a provider survey and contributed data toward a chart review for up to five qualifying patients with DED who initiated lifitegrast ophthalmic solution (index date) between 01/01/2017 (US) or 01/01/2018 (Canada) and 06/30/2019. Patient demographics, treatments, clinical characteristics, and outcomes (ie, severity, signs, symptoms) were collected for the 6-month pre-index period and up to 12-months post-index. Results For this study, 517 HCPs contributed 600 patient charts. Among 554 and 281 patients with follow-up at 6 and 12-months post-index, 512 (92.4%) and 238 (84.7%) patients had ongoing lifitegrast treatment, respectively. Other DED-related treatments were less frequently used post-index with lifitegrast vs pre-index: over-the-counter artificial tear use (45.2% vs 75.5%), topical corticosteroids (3.8% vs 18.8%), any cyclosporine (3.0% vs 20.5%). At 3-months (n=571) and 12-months (n=320) post-index vs pre-index, fewer patients had eye dryness (47 [8.2%] and 16 [5.0%] vs 525 [87.5%]), blurred vision (28 [4.9%] and 11 [3.4%] vs 346 [57.7%]), ocular burning/stinging (25 [4.4%] and 8 [2.5%] vs 336 [56.0%]), depression (8 [1.4%] and 9 [2.8%] vs 55 [9.2%]), fatigue (4 [0.7%] and 1 [0.3%] vs 82 [13.7%]), and headache (1 [0.2%] and 0 vs 19 [3.2%]). At 3 and 12-months post-index vs pre-index, average corneal staining score was numerically lower (2.7 and 2.0 vs 6.5), and average Schirmer score (10.6 and 10 vs 6.3) and tear film break-up time (7.3 and 8.0 vs 4.8) higher. Conclusion The majority of patients had ongoing lifitegrast treatment 6-months post-index with reduction in overall treatment burden. Improvement in DED signs and symptoms, including QoL impacts, was evident at 3 months and up to 12 months after lifitegrast initiation.

show abstract

“…2 In Canada, the prevalence of DED has been estimated at 21%. 3 Diagnosis of DED should consider symptomatology, visual disturbance, tear film stability and composition, tear volume, damage and/or inflammation of the ocular surface, and eyelid aspects (e.g., blepharitis, lid wiper epitheliopathy). 4,5 In particular, the major cause of DED needs to be recognized before treatment plans can be developed.…”

Section: Introductionmentioning

confidence: 99%

“…The copyright holder for this preprint this version posted October 9, 2020. ; https://doi.org/10.1101/2020.10.07.20207225 doi: medRxiv preprint costs and QoL in Canada. 2,3,10 The present study aimed to contribute to the literature on DED by capturing the direct and indirect cost estimates of DED, stratified by the severity of DED, and to understand the impact upon QoL for Canadian patients with DED.…”

Section: Introductionmentioning

confidence: 99%

Dry eye disease: A Canadian quality of life and productivity loss survey

Chan

Ziai

Myageri³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Aim: To capture the direct and indirect cost estimates of dry eye disease (DED), stratified by disease severity, in patients from Canada and to understand the impact of DED on quality of life (QoL) in this group. Methods: A prospective, multi-centre, observational, cross-sectional study was conducted at six optometry and ophthalmology sites across Canada. Eligible patients completed a 20-minute survey on demography, general health, disease severity, QoL, and direct and indirect costs. Results: A total of 151 patients participated in the study and 146 were included in the analysis. Mean (standard deviation [SD]) age was 49.8 (11.4) years and most patients were female (89.7%). DED was considered moderate or severe by 19.2% and 69.2% of patients, respectively. Sjögren's syndrome was reported by 8.2% of patients. Total mean annual costs of DED were $24,331 (Canadian dollars [CAD]) per patient and increased with disease severity. Mean (SD) indirect costs for mild, moderate, and severe disease were $5,961 ($6,275), $16,525 ($11,607), and $25,485 ($22,879), respectively. Mean (SD) direct costs were $958 ($1,216), $1,303 ($1,574), and $2,766 ($7,161), respectively. QoL scores were lowest in patients with Sjögren's syndrome and those with severe DED. Conclusions: This study provides important insights into the negative impact of DED in a Canadian setting. Patients with severe DED reported higher direct and indirect costs and lower QoL compared with those with mild or moderate disease. Increased costs and poorer QoL were also evident for patients with DED plus Sjögren's syndrome versus DED alone.

show abstract

Prevalence of dry eye disease in Ontario, Canada: A population-based survey

Cited by 49 publications

References 18 publications

Association between asthma with dry eye disease

Association between asthma with dry eye disease

Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra®) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease

Dry eye disease: A Canadian quality of life and productivity loss survey

Contact Info

Product

Resources

About